Archives

  • 2019-10
  • 2019-11
  • 2020-03
  • 2020-07
  • 2020-08
  • br Acknowledgments The National Cancer Database

    2020-08-12


    Acknowledgments: The National Cancer Database (NCDB) is a joint project of the Commission on Cancer of the American College of Surgeons and the American Cancer Society. The Commission on Cancer’s NCDB and the hospitals participating in the NCDB are the source of the de-identified data used herein; they 56-75-7 have not verified and are not responsible for the statistical validity of the data analysis or the conclusions derived by the authors. The authors would like to thank the Commission on Cancer and the American Cancer Society for the creation and maintenance of the NCDB.
    We thank Anna Krasnova, MHS, of the Center for Surgery and Public Health at Brigham and Women’s Hospital for her assistance in the revision of this manuscript.
    Appendix A. Supplementary data
    References
    [1] Bolla M, Van Tienhoven G, Warde P, et al. External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. Lancet Oncol 2010;11:1066–73.
    [2] Bolla M, de Reijke TM, Van Tienhoven G, et al. Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med 2009;360:2516–27. [3] Denham JW, Steigler A, Lamb DS, et al. Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced pros-tate cancer: 10-year data from the TROG 96.01 randomised trial. Lancet Oncol 2011;12:451–9.
    [9] Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estra-mustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351:1513–20.
    [14] Vale CL, Burdett S, Rydzewska LH, et al. Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data. Lancet Oncol 2016;17:243–56.
    [16] Bilimoria KY, Stewart AK, Winchester DP, Ko CY. The National Cancer Data Base: a powerful initiative to improve cancer care in the United States. Ann Surg Oncol 2008;15:683–90.
    [17] Nieto FJ, Coresh J. Adjusting survival curves for confounders: a review and a new method. Am J Epidemiol 1996;143:1059–68. [18] Epstein JI, Egevad L, Amin MB, et al. The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason grad-ing of prostatic carcinoma: definition of grading patterns and proposal for a new grading system. Am J Surg Pathol 2016;40:244–52. [19] Pilepich MV, Winter K, Lawton CA, et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma—long- 
    [20] Roach M, 3rd, Bae K, Speight J, et al. Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610. J Clin Oncol 2008;26:585–91.
    [22] D’Amico AV, Chen MH, Renshaw A, Loffredo M, Kantoff PW. Long-term follow-up of a randomized trial of radiation with or without androgen deprivation therapy for localized prostate cancer. JAMA 2015;314:1291–3.
    [23] Zapatero A, Guerrero A, Maldonado X, et al. High-dose radiotherapy with short-term or long-term androgen deprivation in localised prostate cancer (DART01/05 GICOR): a randomised, controlled, phase 3 trial. Lancet Oncol 2015;16:320–7.
    [24] Denham JW, Joseph D, Lamb DS, et al. Short-term androgen sup-pression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): an open-label, randomised, phase 3 factorial trial. Lancet Oncol 2014;15:1076–89.
    [26] Tilki D, Schaeffer EM, Evans CP. Understanding mechanisms of resistance in metastatic castration-resistant prostate cancer: the role of the androgen receptor. Eur Urol Focus 2016;2:499–505.
    [27] Spratt DE, Evans MJ, Davis BJ, et al. Androgen receptor upregulation mediates radioresistance after ionizing radiation. Cancer Res 2015;75:4688–96. [28] National Comprehensive Cancer Network. Prostate cancer, version 2.2017. Available at: https://www.nccn.org/professionals/ physician_gls/f_guidelines.asp. Accessed March 14, 2017.
    [29] Muralidhar V, Catalano PJ, Reznor G, et al. Variation in national use of long-term ADT by disease aggressiveness among men with unfavorable-risk prostate cancer. J Natl Compr Canc Netw 2016;14:421–8.
    Contents lists available at ScienceDirect
    Cancer Letters
    journal homepage: www.elsevier.com/locate/canlet
    Original Articles
    Androgen deprivation-induced ZBTB46-PTGS1 signaling promotes T
    neuroendocrine differentiation of prostate cancer